REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - TAKEDA PHARMACEUTICAL
RNS Number : 3218VMorgan Stanley20 July 2018
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader:
Morgan Stanley MUFG Securities Co., Ltd.
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical Company Limited
(c) Name of the party to the offer with which exempt principal trader is connected:
Shire plc
(d) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
19 JULY 2018
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES - Shire plc
2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
3,040,293
0.39
8,440,752
1.08
(2) Cash-settled derivatives:
8,363,922
1.07
2,666,000
0.34
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
0
0.00
0
0.00
TOTAL:
11,404,215
1.46
11,106,752
1.42
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
N/A
Details, including nature of the rights concerned and relevant percentages:
N/A
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchases/sales
Total number of securities
Highest price per unit paid/received
Lowest price per unit paid/received
Ordinary
PURCHASES
608,464
4,791.0000 JPY
4,731.0000 JPY
Ordinary
SALES
744,082
4,793.0000 JPY
4,732.0000 JPY
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary
CFD
LONG
100
4771.0000 JPY
Ordinary
CFD
LONG
9600
4762.7948 JPY
Ordinary
CFD
LONG
300
4780.6666 JPY
Ordinary
CFD
LONG
4300
4753.9958 JPY
Ordinary
CFD
LONG
8800
4762.4313 JPY
Ordinary
CFD
SHORT
9400
4756.6276 JPY
Ordinary
CFD
LONG
9800
4749.7448 JPY
Ordinary
CFD
SHORT
200
4781.5000 JPY
Ordinary
CFD
LONG
200
4740.0000 JPY
Ordinary
CFD
LONG
500
4762.6000 JPY
Ordinary
CFD
SHORT
2500
4740.0000 JPY
Ordinary
CFD
SHORT
24900
4747.5100 JPY
Ordinary
CFD
LONG
18700
4765.8502 JPY
Ordinary
CFD
LONG
800
4760.2500 JPY
Ordinary
CFD
LONG
100
4785.0000 JPY
Ordinary
CFD
LONG
1100
4734.0000 JPY
Ordinary
CFD
LONG
1500
4784.3893 JPY
Ordinary
CFD
LONG
100
4750.0000 JPY
Ordinary
CFD
LONG
900
4765.4444 JPY
Ordinary
CFD
LONG
7400
4743.1868 JPY
Ordinary
CFD
SHORT
23300
4752.5206 JPY
Ordinary
CFD
SHORT
20100
4734.0000 JPY
Ordinary
CFD
LONG
20100
4734.0000 JPY
Ordinary
CFD
SHORT
20100
4752.5206 JPY
Ordinary
CFD
SHORT
2100
4732.0357 JPY
Ordinary
CFD
LONG
4600
4730.2173 JPY
Ordinary
CFD
SHORT
6300
4732.0357 JPY
Ordinary
CFD
LONG
166998
4758.2878 JPY
Ordinary
CFD
SHORT
3380
4742.3968 JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
N/A
N/A
N/A
N/A
N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
N/A
N/A
N/A
N/A
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
NO
Date of disclosure:
20 JULY 2018
Contact name:
Craig Horsley
Telephone number:
+44(141) 245 7736
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDFEOEAEXEASEPEFF
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement